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Abstract
Background: Activated Protein C Resistance (APCR), a poor anticoagulant response of APC in haemostasis, is the
commonest heritable thrombophilia. Adverse outcomes during pregnancy have been linked to APCR. This study
determined the frequency of APCR, factor V gene known and novel SNPs and adverse outcomes in a group of
pregnant women.
Methods: Blood samples collected from 907 pregnant women were tested using the Coatest® Classic and
Modified functional haematological tests to establish the frequency of APCR. PCR-Restriction Enzyme Analysis (PCR-
REA), PCR-DNA probe hybridisation analysis and DNA sequencing were used for molecular screening of known
mutations in the factor V gene in subjects determined to have APCR based on the Coatest® Classic and/or
Modified functional haematological tests. Glycosylase Mediated Polymorphism Detection (GMPD), a SNP screening
technique and DNA sequencing, were used to identify SNPs in the factor V gene of 5 APCR subjects.
Results: Sixteen percent of the study group had an APCR phenotype. Factor V Leiden (FVL), FV Cambridge, and
haplotype (H) R2 alleles were identified in this group. Thirty-three SNPs; 9 silent SNPs and 24 missense SNPs, of
which 20 SNPs were novel, were identified in the 5 APCR subjects. Adverse pregnancy outcomes were found at a
frequency of 35% in the group with APCR based on Classic Coatest® test only and at 45% in the group with APCR
based on the Modified Coatest® test. Forty-eight percent of subjects with FVL had adverse outcomes while in the
group of subjects with no FVL, adverse outcomes occurred at a frequency of 37%.
Conclusions: Known mutations and novel SNPs in the factor V gene were identified in the study cohort
determined to have APCR in pregnancy. Further studies are required to investigate the contribution of these novel
SNPs to the APCR phenotype. Adverse outcomes including early pregnancy loss (EPL), preeclampsia (PET) and
intrauterine growth restriction (IGUR) were not significantly more frequent in subjects with APCR compared to
normal pregnant women however Pregnancy induced hypertension (PIH) was found to be associated with FVL in
our study group.
Background
APCR produces a thrombophilic state [1,2]. The combi-
nation of inherited thrombophilia and pregnancy greatly
increases the risk of venous thromboembolism (VTE),
which remains the commonest cause of maternal death
in the developing world [3]. Thrombophilia has been
linked to SNPs including Factor V G1691A (FV Leiden)
(FVL), FII G20210A and MTHFR-C677T [4,5]. FVL is
the commonest inherited prothrombotic SNP associated
with APCR amongst Caucasians [6,7]. Other SNPs
located in the factor V gene have the potential to contri-
bute to the APCR phenotype either independently or
found in association with the FVL mutation. These include
Cambridge Arg
306, Hong Kong Arg
306,t h eA r g
679
and the haplotype (H) R2 and R3 polymorphisms [8-13].
There are conflicting reports as to the association
between some of these factor V gene mutations and the
APCR phenotype [14,15]. A number of studies have
reported the finding of APCR during pregnancy without
an obvious genetic cause [16,17]. APCR in those cases,
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by which pregnancy induces a prothrombotic state.
Acquired APCR in pregnancy is due to decreased levels
of Protein S while Factor VIII levels have been reported
to have an inverse correlation with APCR in pregnancy
[18-21].
In this study, we screened pregnant women with
APCR for known mutations and haplotypes in the factor
V gene. We investigated the factor V gene in selected
pregnant women with APCR for novel SNPs using
GMPD, a novel mutation detection technology [22]. We
determined the frequencies of adverse pregnancy out-
comes in subjects with APCR based on the Classic
Coatest® test only and in the group with APCR based on
the Modified Coatest® test. The association of FVL with
EPL, PET, PIH and IUGR was also examined.
Methods
Subjects
Written consent for samples to be collected and ethical
approval for the study were obtained from the Research
Ethics Committee at the University College Hospital,
Galway, (UCHG) and from the 907 pregnant women
included in this study attending the antenatal clinic at
UCHG. Blood samples (Lithium Heparin and EDTA)
were collected from these women who were ranging
from 16
th to 24
th weeks gestation. The second trimester
was chosen for the assessment of APC status by Coat-
est® Classic and Modified functional haematological tests
as previous studies had shown that there is little or no
variation of the coagulation factors at that stage of preg-
nancy [23].
Coatest® haematological tests
Blood samples taken from pregnant women were drawn
into evacuated anticoagulant tubes (9 volumes of blood
into 1 volume of 3.2% (w/v) tri-Sodium Citrate solu-
tion). After centrifugation for 15 min at 3000 × g the
plasma was stored at -80°C until they were tested using
the Coatest® Classic test (Chromogenix), as described by
Axelsson [24]. This test measures the ratio of activated
partial thromboplastin time (APTT) in the presence and
absence of exogenous APC. APCR is characterised by a
minimal prolongation of the APTT in response to APC
and a correspondingly low ratio is determined. APCR
was defined as a ratio of less than or equal to 2.1 s and
APC normal as greater than 2.1 s. The 2.1 s cut off is
the value established in clinical use at the hematology
department in UCHG.
Acquired APC resistance tests
Factors V, VIII and IX were determined from the classic
and modified APC resistance samples and 50 APC nor-
mal samples using a one stage APTT assay on a MDA
180 coagulometer (Organon Teknika, Cambridge, UK),
using factor V, VIII and IX deficient plasma’s (Diagnos-
tica Stago). Results were expressed as percentage (%)
levels. Each run was controlled by the use of a normal
(MDA verify1, Biomerieux) and abnormal control (coa-
gulation control A, Technoclone GmbH).
DNA extraction
DNA was extracted from blood samples for all APCR sub-
jects (n = 140) using a modification of the CF(12)m-PCR
protocol by Ortho-Clinical Diagnostics, Amersham, UK.
Screening for known thrombophilic mutations
PCR-Restriction enzyme analysis (PCR-REA) was applied
to identify: FVL, FV Cambridge, FV Hong Kong muta-
tions and Haplotype (H) R2, R3 alleles in the factor V
gene. DNA probe hybridisation analysis and/or DNA
sequencing was applied for Arg
679 mutation detection.
Mutations were screened in duplicate, a PCR negative
control and homozygous and heterozygous controls for
the different mutations were included in the screening
where available. PCR amplification was performed on the
GeneAmp PCR System 9600 (Perkin Elmer, USA). PCR-
REA reactions were performed as referenced [8,25-28]
and all PCR reagents were obtained from Promega
(Madison, USA). PCR constituents were made up to a
final volume of 100 μl with DNAase/RNAase free water
(Sigma Aldrich, UK). Screening for the Arg
679 mutation
used primer set Fow 5’TgCCACAATggATTATTgTg’3
and Rev 5’AgAAACgAATTCAgTgCCAT’3 to amplify a
400 bp fragment. PCR reaction was made up to a final
volume of 100 μl with DNAase/RNAase free water (Sigma
Aldrich, UK). PCR included MgCl2 3.5 mM, 0.2 mM
dNTP, in a 1 × PCR reaction buffer (10 mM Tris-HCl, 50
mM KCl, 0.1% Triton ×-100), from Promega (Madison,
USA). The PCR amplification included 1 cycle of dena-
turation at 10 min 94°C, a second step of 35 cycles of: 1
min denaturation at 94°C, 1 min at annealing at 57°C and
1 min extension at 72°C, and a third final elongation step
at 72°C for 5 min followed by holding at 4°C at the end of
the reaction. A combination of 3 DNA hybridisation
probes including 2 controls for the wild-type sequence
(5’CATggCTACACggAAAATgCATg’3, 5’gTTAACTTC-
CATgAATTCTAgTCCAAg’3) and a mutant probe
(5’gTTAACTTCgATgAATTCTAgTCCAAg’3) were
designed from factor V sequence (GenBank Accession
number AY364535) to identify mutations in the Arg
679
cleavage site of the factor V gene following amplification
with the Arg
679 site primers.
Adverse pregnancy outcomes
An evaluation of the outcomes of pregnancy including;
EPL, PET, PIH and IUGR was performed by examination
of maternity records at UCHG for the study subjects The
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12 weeks gestation (spontaneous abortion or ectopic).
PET-BP (Blood pressure) ≥ 140/90 mmHg, +1 proteinuria
and oedema. PIH-BP ≥ 140/90 with no proteinuria in
accordance with the Official Journal of the International
Society for the Study of Hypertension in Pregnancy.
IUGR-is defined as fetal growth of less than 5
th percentile
for gestational age [29].
Statistical analysis
The Chi-Square test from SPSS version 17.0 software was
performed to test if there was a significant difference in
the proportion of the different outcomes in the subjects
with APCR with only the Classic Coatest® test (n = 105)
compared to the subjects with APCR based on the Modi-
fied Coatest® test (n = 35). The same statistical analysis
was also performed to compare each adverse outcome
type in FVL subjects (n = 29) with subjects without FVL
(n = 878). Ninety-five percent Confidence intervals (CI)
were determined. The Kruskal-Wallis statistical test
http://www.graphpad.com was applied to compare levels
of FV, FVIII and FIX in APCR and APC normal pregnant
subjects. P values < 0.05 were considered significant.
Screening for novel thrombophilic mutations by GMPD
Five patients with APCR and 1 APC normal control sub-
ject were selected for scanning for SNPs in the factor V
gene by glycosylase mediated polymorphism detection
(GMPD) analysis. The normal dTTP nucleotide is par-
tially modified by introducing dUTP during PCR amplifi-
cation for the GMPD. PCR primers (Additional file 1,
Table S1) to amplify all 25 exons of factor V gene were
designed using the Primer3 program http://www-genome.
wi.mit.edu/cgi-bin/primer/primer3_www.cgi and the fac-
tor V sequence GenBank Accession number Z99572.
PCR was optimised to determine optimal MgCl2 and
annealing temperature conditions for amplification of fac-
tor V exons (Additional file 1, Table S1). Primers were
synthesised by TIB MOLBIOL, (Germany) with a 5’
fluorescent label modification, 6-FAM (6-carboxyfluores-
cein) on the forward primer and a 5’HEX (hexachlori-
nated analogue of 6-FAM) modification on the reverse
primer to perform GMPD analysis on both strands of the
PCR products. PCR reactions were performed in dupli-
cate in 20 μl volume and included approximately 30-50
ng genomic DNA, 1.5 U Taq polymerase, 12.5 pmol of
each appropriate labeled PCR primer, MgCl2 concentra-
tion as appropriate to the PCR primer set pair (Addi-
tional file 1, Table S1) and 0.2 mM of each of dATP,
dCTP, dGTP, and 1:60 ratio of dTTP: dUTP in distilled
H2O. PCR product (10 μl) was mixed with 1 μl of 0.5 U/
μl exonuclease I (New England Biolabs, UK) and incu-
bated at 80°C for 15 min. The exonuclease I treated PCR
product mix was purified on an A S300HR clean-up
column (Amersham Pharmacia Biotech, England) follow-
ing manufacturers instructions. The purified PCR pro-
ducts were incubated at 37°C for 30 min with one
microlitre of 0.5 U/μl uracil DNA-glycosylase (New Eng-
land Biolabs, UK) to cleave the N-glycosidic bond
between the base uracil and the sugar deoxyribose in the
DNA molecule. This reaction generates an apyrimidinic
(AP) site. The AP site was cleaved chemically by adding
1 μl of 0.6 M NaOH (Sigma Chemical, USA) (final con-
centration of 0.05 M NaOH) to the reaction mix and
incubated at 95°C for 15 min. To neutralise the reaction,
1 μl of 0.45 M Tris base (Sigma Chemical, USA) (final
concentration of 0.03 M) was added. One microlitre of
GeneScan internal standard (ROX-500; PE, Applied Bio-
systems, USA) was also added to each sample. Prior to
analysis by electrophoresis on a 6% PAGE (7 M urea),
denaturation of samples was performed by adding 1 μlo f
deionised formamide (Applied Biosystems, USA) and 2 μl
of 50 mg ml
-1 blue dextran dye in 25 mM EDTA (Sigma
Chemical, USA). The mixture was heated at 95°C for 5
min prior to the run. The ABI PRISM 377 automated
DNA sequencer (Applied Biosystems, PE, USA) was set
at 3 kV/h for 6 h using filter A at 2400 scans/h.
DNA sequencing
PCR products from selected subjects screened for the
Arg
679 mutation and PCR products that were identified
to contain an SNP by GMPD were sequenced. PCR pro-
ducts were purified using the QIAprep Spin Miniprep
Kit (Qiagen Ltd, UK) according to the manufacturers
instructions and sent to a commercial sequence service
provider (MWG Biotech, Germany) for sequencing.
Analysis of amino acid changes resulting from
detected SNPs
T h em R N As e q u e n c eo ff a c t o rV( 6 9 1 3b pn u c l e o t i d e s ,
GenBank Accession number NM_000130) was translated
into its protein product using the internet translation tool
at http://us.expasy.org/tools/dna.html which identified
each amino acid and its corresponding codon sequence.
The nucleotide and amino acid sequences for each exon
were compared with the sequences reported by Jenny
et al. (1987). Other sequences were also included to com-
pare the nucleotides and amino acids changes at posi-
tions where SNPs were identified in this study, these
sequences included the following GenBank Accession
numbers: NP_000121, NM_000130, M16967, Z99572 and
XM_001575.
Results
Description of study cohort
We determined that 16% (n = 140) of pregnant women
tested had APCR, 12% of whom had APCR based on
Classic Coatest® test and 4% had APCR with the Classic
Sedano-Balbás et al. BMC Pregnancy and Childbirth 2010, 10:11
http://www.biomedcentral.com/1471-2393/10/11
Page 3 of 8and Modified Coatest® tests. One subject had APCR
with the Modified Coatest® test only. Eighty-nine Classic
APCR subjects had no known mutations in the factor V
gene. Sixteen subjects had the FV HR2 haplotype.
Thirty-four subjects were identified to have APCR based
on the Classic and Modified test, 29 of whom had the
FVL mutation. One subject with FVL also had the FV
Cambridge-G1091C mutation (Table 1).
Measurement of Factor V, Factor VIII and Factor IX
in subjects with classic APCR and modified APCR
determined the levels of Factor V to be significantly
decreased and the levels of Factors VIII and IX to be
significantly increased compared to normal pregnant
controls.
Novel SNPs identified in APCR subjects with Modified
Coatest® test and without FVL
We selected five subjects for investigation for novel
SNPs in the factor V gene because they had APCR with
the Modified Coatest® test and no FVL or other known
mutations in the APC cleavage sites of factor V gene.
Subject 1, a carrier of (H) R2 allele had 9 SNPs in the
factor V gene at nucleotide positions 1216 in exon 8,
2325, 2297/8, 3015, 4038, 4047 and 4648 in exon 13
and 5380 in exon 16; subject 2 had 10 SNPs in the fac-
tor V gene at nucleotide positions 1216/7, 1219 and
1226 in exon 8, 1977 in exon 12 and 2904, 3894, 4040/1,
4185 in exon 13; subject 3 had 5 SNPs in the factor V
gene at nucleotide positions, 2663, 2684, 2710, 2887 and
4125 in exon 13; subject 4 had 5 SNPs in the factor V
gene at nucleotide positions 2127, 2298, 2391 and 2893/4
in exon 13 and subject 5 had 4 SNPs in the factor V gene
at nucleotide positions 2863, 2883, 2884/5, in exon 13.
In total, 33 polymorphisms were identified, in 5 cases
(2297/8, 1216/7, 2893/4, 2884/5, 4040/1) two SNPs were
i d e n t i f i e di nt h es a m ec o d o n .A l lt h eS N P sw e r ec o n -
firmed in duplicate samples and by comparison to Gen-
Bank sequence NM_000130 and other available factor V
sequences. Table 2 summarises the SNPs detected by
GMPD and identified by DNA sequencing in this study.
Adverse outcomes
Table 3 shows the type and number of adverse preg-
nancy outcomes in subjects with APCR, based on the
Classic Coatest® test (n = 105) only, compared to the
subjects with APCR based on the Modified Coatest® test
(n = 35). Table 3 also shows a comparison of adverse
outcomes in FVL subjects (n = 29) with subjects without
FVL (n = 878). No significant difference was found in
the frequency for EPL, PET or IUGR between the
groups compared. However PIH had a significantly
higher frequency in subjects with APCR based on the
Modified Coatest® test (Chi-Square p value 0.018) com-
pared to subjects with APCR based on the Classic Coat-
est® test only. PIH frequency was also significantly
different (Chi-Square-p value 0.004) in FVL subjects
compared to the subjects with no FVL.
Discussion
Factors that are thought to contribute to APCR in the
general population and during pregnancy include defects
in the Factor V protein, most frequently caused by the
Leiden mutation [1,30]. Several reports have shown
however that between 5-10% of APCR does not involve
the FVL and the cause of APCR in these cases is not
known [1,8,31-33]. APCR in these cases may be the
result of acquired factors including pregnancy. The fre-
quency of acquired APCR in our study group, indicated
by women showing APCR with Classic Coatest® test
tested in the second trimester only was 12%. This corre-
lates with various studies showing reduced APC ratios
in the Classic Coatest® test during pregnancy [34,35].
T e s t i n go ft r u eA P C Rs t a t u si nt h es t u d yc o h o r tb ya
second measurement of APC at pre-pregnancy or 8 to
12 weeks post-pregnancy or more frequently during
pregnancy was not performed and this is a major limita-
tion of the current study. Mahieu et al. (2007) recently
reported an inverse correlation between increasing Fac-
tor VIII and decreasing APC sensitivity ratio in second
trimester pregnant women. Increasing Factor VIII has
been linked to early pregnancy loss [36]. In our study
we found the levels of Factors VIII to be significantly
increased in APCR subjects compared to normal preg-
nant controls. Overall FVL frequency in our study
group (n = 907) was 3.1% which is slightly lower than
the range of 4-7% reported in previous Irish studies
[37,38] but within the range of prevalence of FVL in the
Table 1 Distribution of known mutations in the
Factor V gene
APCR with Classic Coatest® test only n = 105
Frequency % n mutation
15 16 ht (H) R2
85 89 no mutations
APCR with Classic and Modified Coatest® test n = 34
Frequency % n mutation
85 29 hz FV Leiden
3 1 hz Cambridge*
1
3 1 hz (H) R2
14 4 no mutations
APCR with Modified Coatest® test only n = 1
Frequency % n mutation
100 1*
2 no mutations
Abbreviations: (n) number of subjects, (ht) heterozygotes, (hom) homozygotes,
(H) haplotype.
*
1 n = 1 had hz Cambridge and FVL mutations simultaneously.
*
2 Subject was not included in the scanning for novel SNPs as insufficient
DNA sample was available for the study.
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APCR with the Modified Coatest® test did not have the
FVL suggesting that Coatest® test can give false positive
results.
APCR has been considered a risk factor for thrombo-
sis in pregnancy and it has been suggested that pregnant
women who have had previous thrombotic events or
who have a family history of the FVL mutation should
be screened for the FVL mutation [40]. Other mutations
in the factor V gene, particularly at the other cleavage
sites, Arg
306 and Arg
679 of Factor V have the potential
to contribute to the APCR phenotype [8,41]. No muta-
tions have been identified to date at Arg
679 in this or
other studies [42], Van der Neut Kolfschoten, 2005 (per-
sonal communication).
One subject in our APCR cohort had 2 mutations in
the factor V gene; FVL and FV Cambridge G1091C, this
subject developed PIH during pregnancy. A recent
Spanish study identified the FVL and FV Cambridge
mutations in a subject with a family history of thrombo-
sis [43].
Haplotypes (H) R2/R3 have also been associated with
mild APCR when found in combination with the FVL
[12,15,42]. In our study, the (H) R2 allele was found in
12% of the APCR cohort. We did not identify the (H)
R3 allele mutation in the APCR group which is consis-
tent with published literature [8]. There have been a
number of other mutations identified in other studies
on the factor V gene however they do not appear to
contribute significantly to APCR in Caucasian popula-
tions, for example, R485K and I359T [9,44,45].
It was previously speculated that APCR may be caused
by a novel defect in the factor V molecule [46]. We
Table 2 SNPs identified in the FV gene by GMPD
Non-silent SNPs
SNP identified by GMPD NM_000130 sequence
codon amino acid Exon nucleotide codon amino acid
TTC Phe [F] 13 2127 TTg Leu [L]-651
AAC Asn [N] 13 2297/8 ATT Ile [I] -708
AAA Lys [K]*
1 13 2663 AgA Arg [R]-830
CAT His [H]*
2 13 2684 CgT Arg [R]-837
AAg Lys [K]*
3 13 2863 gAg Glu [E]-897
TCT/TCA Ser [S] 13 “2884/5” TTA Leu [L]-903
TTT/ Phe [F]/ 13 “2884/5” TTA Leu [L]-903
gTC Val [V] 13 2887 CTC Leu [L]-904
ATA/ Ile [I]/ 13 “2893/4” AAA Lys [K]-906
CAA/ Glu [E]/ 13 “2893/4” AAA Lys [K]-906
CTA Leu [L] 13 “2893/4” AAA Lys [K]-906
AAg Lys [K] 13 2904 AAC Asn [N]-909
AAT Asn [N] 13 4040/1 ggT Gly [G]-1289
ATA Ile [I] 13 4047 ATg Met [M]-1291
Cgg Arg [R] 13 4125 CAg Glu [Q]-1308
TCA Ser [S] 13 4648 ACA Thr [T]-1492
Atg Met [M]*
4 16 5380 gTg Val [V]-1736
Ggg Gly [G] 8 1216 Agg Arg [R]-348
CAg Gln [Q] 8 1216/7 Agg Arg [R]-348
CCT Pro [P] 8 1219 TCT Ser [S]-349
CTT Leu [L] 8 1226 CAT His [H]-350
CAA Gln [Q] 12 1977 CAC His [H]-601
Silent SNPs
SNP identified by GMPD NM_000130 sequence
Codon amino acid exon nucleotide codon amino acid
ATA Ile [I] 13 2298 ATT Ile [I]-708
AAC Asn [N] 13 2325 AAT Asn [N]-712
TCA Ser [S] 13 2391 TCg Ser [S]-739
gAA Glu [E] 13 2710 CAA Gln [Q]-846
CTA Leu [L] 13 2883 CTg Leu [L]-902
CCT Pro [P] 13 3015 CCC Pro [P]-947
TCC Ser [S] 13 3894 TCT Ser [S]-1240
CTT Leu [L] 13 4038 CTC Leu [L]-1288
ACT Thr [T] 13 4185 ACC Thr [T]-1337
Notes:
Nucleotide and amino acid positions presented in this table correspond to
GenBank sequence NM_000130. When (/) appears between nucleotide bases,
it indicates that the SNPs were found in the same codon. The (“” ) indicate
that there were identified possible amino acids encoded by the SNPs at that
nucleotide position. The amino acids at codon residues 348 and 708 appear
twice in the table as they were found in different subjects with different SNPs.
Abbreviations: (A) adenine, (G) guanine, (T) thymine and (C) cytosine.
*
1 [R] in NP_000121, NM_000130, M16967 and [K] in Z99572, XM_001575.
*
2 [R] in NP_000121, NM_000130, M16967 and [H] in Z99572, XM_001575.
*
3 [E] in NP_000121, NM_000130, M16967 and [K] in Z99572, XM_001575.
*
4 [V] in NP_000121, NM_000130, M16967 and [M] in Z99572, XM_001575.
Table 3 Adverse obstetric outcomes
Subjects identified (n) Type and number of adverse pregnancy
outcomes
APC resistance n = 140 EPL PET PIH IUGR
Only Classic n = 105 29/105 2/105 5/105 1/105
Modified n = 35 9/35 1/35 6/35 0/35
Chi-Square p value .826 .736 .018 .562
Subjects identified (n) Type and number of adverse pregnancy
outcomes
Total cohort n = 907 EPL PET PIH IUGR
No FVL n = 878 226/878 41/878 43/878 21/878
FVL n = 29 8/29 1/29 5/29 0/29
Chi-Square p value .832 .748 .004 .396
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subjects scanned for SNPs by GMPD. A number of the
SNPs (nucleotide positions 2663, 2684, 2863, 5380) were
identified previously in GenBank sequences of Factor V
(NP_000121, NM_000130, M16967, Z99572 or
XM_001575). The identification of these SNPs by
GMPD validated the SNP scanning technique we used.
Previous studies defined the R2-H1229A haplotype
polymorphism as a combination of mutations includ-
ing, C2298T, T2325C, A2379G, A2391G and A4070G
(HR3) in exon 13 and A5380G in exon 16 [11,12,47].
In our study, the heterozygous carrier of R2 allele-
H1229A was determined to have T2298A, T2325C,
and G5380A SNPs. The haplotype (H) R2 has also
been linked to altered levels and ratios of Factor V1
and Factor V2 [11,45]. We also found G2391A SNP,
previously associated with the HR2 haplotype, in one
subject. Four of the novel SNPs identified in this
study are located in exon 8 while most exons have no
SNPs identified in this study. This may suggest that
Factor V amino acids 348-350 have an association
with APCR.
In a study performed by Kostka et al. (2000), the pre-
sence of missense mutations in the first 1200 bp of the
Exon 13 (B-domain) of the factor V gene was investigated
in a group of APCR patients who did not carry the FVL
mutation. Four silent mutations, C2298T, T2325C,
A2379G, A2391G and four missense mutations; A2540C,
A2663G, A2684G, A2863G were identified in patients
with thrombosis and normal controls [48]. In our study
the SNP T2325C was identified and SNPs at nucleotide
positions 2298(T2298A), 2391(G2391A), 2663(G2663A),
2684(G2684A) and 2863(G2863A) were also identified.
SNP T3894C identified in our study was also previously
identified in a study performed on factor V levels in
plasma by Lunghi et al. (1996). Twenty-six of the SNPs
identified in this study, were in exon 13 which encodes
most of the B domain of the FV protein. This high fre-
quency of SNPs in exon 13 has been previously reported
[26,49]. The large heavily glycosylated B-domain, span-
ning amino acids 710-1545, was previously reported not
to be essential for the cofactor activity of the FV glyco-
protein as it is released during the activation of FV
[50,51]. However, other studies have postulated that the
B domain may be involved in other coagulation related
functions including the proteolytic activation of throm-
bin. A previous study showed decreased activation of
thrombin when the B domain of FV was completely
deleted [52]. Kostka et al. (2000) suggested that the B
domain of FV is of vital importance in APC cofactor
activity in the clotting cascade, and that mutations in this
domain may contribute to an ineffective APC response.
The C-terminal part of the B-domain (residues 1477-
1545) was suggested to be crucial for the APC-cofactor
function [53]. It has also been suggested that a region of
FV B domain may function in Factor VIII (a) inactivation
by APC through the FV-PS-APC system [54-56]. Muta-
t i o n si ne x o n1 3m a yd i s r u p tt h ec a l c i u m - b i n d i n gs i t ei n
the FV protein leading to a loss of the high-affinity (cal-
cium-dependent) interaction of the heavy chain and light
chain of FVa potentially influencing the dissociation of
the heavy chain and light chain [57-59].
Dawood et al. (2007) found significant increased fre-
quency of SNPs in the factor V gene in the women with
acquired APCR and recurrent miscarriage in comparison
with their control groups [60]. In our study we identi-
fied several SNPs in the Modified APCR subjects with
no FVL. The finding of 20 novel factor V gene SNPs in
these subjects is interesting. These SNPs may have an
effect on FV levels rather than directly causing APCR. A
future study screening the normal population would be
useful to determine if these SNPs are common in the
population. It may be that these SNPs are common in
Irish people but rarely found in other populations.
The total frequency of adverse outcomes was not sig-
nificantly different in the group with APCR based on
the Modified test compared to the pregnant group with
classic APCR, which is consistent with the findings of
recent studies [61,62]. Comparison of the frequency of
each adverse outcome individually determined a statisti-
cally significant higher prevalence of PIH in subjects
with APCR with the Modified Coatest® test and in sub-
jects with FVL compared to subjects with no FVL. Of
48 subjects from the total study cohort with PIH, 3 sub-
jects had PET, two of whom had APCR and only one
had FVL. PET in this cohort is associated with changes
to coagulation system other than those caused by FVL.
FVL was significantly associated with PIH in a German
study investigating 70 women with severe PIH, 15 of
whom had PET [63]. In contrast, a study of 100 preg-
nant women with PIH in Turkey did not find a signifi-
cant association between FVL and PIH [64].
Discrepancies as to the association of adverse outcomes
with FVL can be a consequence of study size, presence
of additional thrombophilic factors, different study
design and methodology or differences in the genetic
population studied [65,66].
Conclusions
PIH appeared to be associated with FVL whereas no
association was found between FVL and EPL, PET or
IUGR in our pregnant study group. We identified 6
pregnant women with APCR without FVL in our modi-
fied APCR group. Further studies are required to inves-
tigate the contribution of novel SNPs identified in this
study to the APCR phenotype.
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to amplify all 25 exons of factor V gene. These were designed using the
Primer3 program http://www-genome.wi.mit.edu/cgi-bin/primer/
primer3_www.cgi and the factor V sequence GenBank Accession number
Z99572A.
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